Compare BIIB & CTSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | CTSH |
|---|---|---|
| Founded | 1978 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3B | 28.9B |
| IPO Year | 1996 | 1998 |
| Metric | BIIB | CTSH |
|---|---|---|
| Price | $190.27 | $58.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 18 |
| Target Price | ★ $202.92 | $82.19 |
| AVG Volume (30 Days) | 1.2M | ★ 4.7M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.25% |
| EPS Growth | N/A | ★ 1.11 |
| EPS | ★ 8.79 | 4.56 |
| Revenue | $9,890,600,000.00 | ★ $21,108,000,000.00 |
| Revenue This Year | N/A | $8.17 |
| Revenue Next Year | N/A | $5.06 |
| P/E Ratio | $21.68 | ★ $12.83 |
| Revenue Growth | 2.22 | ★ 6.95 |
| 52 Week Low | $115.28 | $57.39 |
| 52 Week High | $202.41 | $87.03 |
| Indicator | BIIB | CTSH |
|---|---|---|
| Relative Strength Index (RSI) | 58.87 | 38.43 |
| Support Level | $170.52 | $58.11 |
| Resistance Level | $191.82 | $63.06 |
| Average True Range (ATR) | 5.08 | 1.79 |
| MACD | 1.38 | 0.16 |
| Stochastic Oscillator | 88.68 | 19.31 |
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Cognizant Technology Solutions is a multinational IT services provider that offers a range of consulting and business process outsourcing services. Originally founded in India, the company is headquartered in the US and serves enterprise customers spanning the financial services, healthcare, and resources industries. With most of its workforce located in India, Cognizant leverages a global delivery model that helps clients outsource their IT needs to offshore labor.